Technical Analysis for ZGNX - Zogenix, Inc.

Grade Last Price % Change Price Change
grade D 29.97 1.80% 0.53
ZGNX closed up 1.8 percent on Friday, June 5, 2020, on approximately normal volume. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Up
Historical ZGNX trend table...

Date Alert Name Type % Chg
Shooting Star Candlestick Bearish 0.00%
Doji - Bearish? Reversal 0.00%
Multiple of Ten Bearish Other 0.00%
MACD Bearish Signal Line Cross Bearish 1.80%
Multiple of Ten Bearish Other 1.80%
Multiple of Ten Bearish Other 0.81%
Multiple of Ten Bullish Other -0.63%
Outside Day Range Expansion -0.63%
Up 3 Days in a Row Strength -0.63%
Multiple of Ten Bearish Other 1.39%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Zogenix, Inc., a pharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system disorders and pain. Its commercial product includes Sumavel DosePro (sumatriptan injection), a delivery system that offers needle-free subcutaneous administration of sumatriptan for the acute treatment of migraine and cluster headache. The company's lead product candidate, Zohydro, a single-entity extended-release hydrocodone, which has completed Phase III clinical trials for the treatment of moderate to severe chronic pain requiring around-the-clock opioid therapy. It is also developing Relday, an injectable formulation of risperidone, which is in a Phase I clinical trial to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers with 13 years of age and older. Zogenix, Inc. markets and sells its Sumavel DosePro to wholesale pharmaceutical distributors and retail pharmacies in the United States. It has a licensing and distribution agreement with Desitin Arzneimittel GmbH to develop and commercialize DosePro in the European Union, Norway, Switzerland, and Turkey. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in San Diego, California.
Chemistry Pharmaceutical Pain Schizophrenia Central Nervous System Disorders Morphinans Neurochemistry European Union Cell Signaling Ketones Migraine Treatment Of Central Nervous System Disorders Treatment Of Migraine Hydrocodone Severe Chronic Pain Bipolar Disorder Indoles Retail Pharmacies Triptans

Is ZGNX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 57.22
52 Week Low 16.65
Average Volume 721,883
200-Day Moving Average 38.23
50-Day Moving Average 26.95
20-Day Moving Average 28.77
10-Day Moving Average 29.71
Average True Range 1.57
ADX 16.22
+DI 26.96
-DI 15.45
Chandelier Exit (Long, 3 ATRs ) 27.15
Chandelier Exit (Short, 3 ATRs ) 29.60
Upper Bollinger Band 31.61
Lower Bollinger Band 25.93
Percent B (%b) 0.71
BandWidth 19.75
MACD Line 0.80
MACD Signal Line 0.82
MACD Histogram -0.0172
Fundamentals Value
Market Cap 744.48 Million
Num Shares 24.8 Million
EPS -3.42
Price-to-Earnings (P/E) Ratio -8.76
Price-to-Sales 35.07
Price-to-Book 12.08
PEG Ratio -0.43
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 32.69
Resistance 3 (R3) 32.86 32.12 32.24
Resistance 2 (R2) 32.12 31.43 32.04 32.08
Resistance 1 (R1) 31.05 31.00 30.68 30.88 31.93
Pivot Point 30.31 30.31 30.12 30.22 30.31
Support 1 (S1) 29.23 29.62 28.86 29.06 28.01
Support 2 (S2) 28.50 29.19 28.41 27.86
Support 3 (S3) 27.42 28.50 27.70
Support 4 (S4) 27.25